CI vs TOI
CI: A diversified global health services organization providing integrated pharmacy benefits and comprehensive health insurance solutions. TOI: The Oncology Institute is a value-based oncology care provider that manages outpatient cancer treatment through a national network of clinics and integrated specialty pharmacies.
Side-by-side fundamentals
| Metric | CI | TOI | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $291.02 | $5.19 | |
| Market cap as of 2026-07-31 | $75.3B | $519M | |
| P/E as of 2026-07-31 | 11.97 | n/a | |
| PEG as of 2026-07-31 | 1.50 | n/a | |
| Net margin as of 2026-07-31 | +2.3% | -8.0% | CI higher |
| Gross margin as of 2026-07-31 | +9.2% | +15.1% | TOI higher |
| Operating margin as of 2026-07-31 | +3.4% | -6.0% | CI higher |
| ROE as of 2026-07-31 | +15.2% | -482.6% | CI higher |
| ROA as of 2026-07-31 | +4.0% | -26.5% | CI higher |
| Debt / equity as of 2026-07-31 | 0.73 | 14.58 | CI lower |
| Revenue growth (YoY) as of 2026-07-31 | +8.8% | +35.4% | TOI higher |
| Revenue CAGR (3y) SEC XBRL | +15.0% | +25.8% | TOI higher |
| Dividend yield as of 2026-07-31 | +2.2% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-07-31 | 0.31 | 0.40 | |
| 1-year return as of 2026-07-27 close | -1.8% | +41.0% | TOI higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.